Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

Fineline Cube Feb 25, 2026
Company Deals

MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks

Fineline Cube Feb 25, 2026
Company Deals

Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor

Fineline Cube Feb 25, 2026
Company Deals

Dartsbio Licenses PACAP Antibody DS009 to Slate Medicines – $130M Series A Fuels Global Migraine Development

Fineline Cube Feb 25, 2026
Company Deals

Henlius Licenses Serplulimab to Abbott for Emerging Markets – Expands Anti‑PD‑1 Global Footprint

Fineline Cube Feb 25, 2026
Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026
Company Drug

United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential

Fineline Cube Feb 25, 2026
Company Drug

Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD

Fineline Cube Feb 25, 2026
Company Drug

Eli Lilly’s Weekly Insulin Efsitora Alfa Matches Daily Basal Insulins in Reducing A1C Levels

Fineline Cube May 20, 2024

Eli Lilly and Company (NYSE: LLY), a global healthcare company, has announced results from a...

Company Deals

Pharmaron to Sell Proteologix Stake in Upcoming Johnson & Johnson Acquisition

Fineline Cube May 20, 2024

Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759;...

Company Deals

Fosun Pharma Nods to Fosun Health Spin-Off; IPO Venue and Requirements Under Review

Fineline Cube May 20, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company in...

Company Medical Device

Medtronic’s Advanced Mazor X Spinal Surgery Robot Receives Chinese Market Clearance

Fineline Cube May 20, 2024

Medtronic (NYSE: MDT), the US-Irish medical technology giant, has announced that it has received approval...

Company Deals

Zhejiang Huahai Pharmaceutical Co., Ltd Plans Capital Raise for Digital Manufacturing Expansion

Fineline Cube May 20, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a leading Chinese pharmaceutical company, has unveiled plans...

Company Deals

Porton Biologics and SAFE Collaborate to Accelerate Pharmaceutical R&D Services

Fineline Cube May 20, 2024

Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...

Company Drug

Biotherus Inc. Advances PM8002 Bispecific Antibody to Phase III for Triple Negative Breast Cancer

Fineline Cube May 20, 2024

China’s Biotheus Inc. has announced the initiation of a Phase III clinical study for its...

Company Drug

Jiangsu Hengrui’s Camrelizumab/Apatinib Combo Denied FDA Approval Over Manufacturing Issues

Fineline Cube May 20, 2024

The US Food and Drug Administration (FDA) has issued a complete response letter to Jiangsu...

Company Drug

ImmuneOnco Biopharmaceuticals’ CD47 Inhibitor Receives NMPA Go-Ahead for Phase III Trial

Fineline Cube May 20, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced that it has received approval from the National...

Company Digital

Siemens Healthineers and Ruijin Hospital Collaborate to Build Medical Digital Human Metaverse

Fineline Cube May 20, 2024

Siemens Healthineers AG, the German medical technology major, has entered into a strategic partnership with...

Company Drug

CSPC Pharmaceutical’s βKlotho Monoclonal Antibody JMT202 Receives Clinical Trial Approval from NMPA

Fineline Cube May 20, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Roche’s CT-388 Shows Significant Weight Loss in Phase I Clinical Trial for Obesity

Fineline Cube May 20, 2024

Switzerland-based healthcare giant Roche (SWX: ROG) has announced preliminary results from a Phase I study...

Company Deals

Biocytogen Expands Reach to India with GVSAP Partnership for BioMice Models

Fineline Cube May 20, 2024

A recent stock exchange announcement from China-based Biocytogen (HKG: 2315) has highlighted a strategic partnership...

Company

HutchMed Chairman Simon To Steps Down, Dr. Dan Eldar Appointed Successor

Fineline Cube May 20, 2024

HutchMed (NASDAQ: HCM, HKG: 0013) today announced a significant change in leadership with the long-serving...

Company Drug

Eisai to Support Grassroots Healthcare in China with Significant Pariet Donation

Fineline Cube May 20, 2024

Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced its commitment to donate 100,000...

Company Drug

North China Pharmaceutical’s Ormutivimab Approved for Pediatric Use in China

Fineline Cube May 17, 2024

North China Pharmaceutical Group Corporation (SHA: 600812) has announced that it has received approval from...

Company Drug

HutchMed’s Sovleplenib Phase III Results to be Showcased at EHA 2024

Fineline Cube May 17, 2024

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013), a biopharmaceutical company based in China, is preparing...

Company Drug

Shanghai UniCAR-Therapy’s Innovative CAR-T Therapy Targets Breakthrough Designation with IL-6 Silencing

Fineline Cube May 17, 2024

Shanghai UniCAR-Therapy Bio-Medicine Technology Co., Ltd, a leading biopharmaceutical company based in China, is on...

Company Deals

Sol-Gel Technologies Partners with Shenzhen Beimei for Twyneo Commercialization in China

Fineline Cube May 17, 2024

Israel-based dermatology specialist Sol-Gel Technologies Ltd. (NASDAQ: SLGL) has announced the signing of a licensing...

Company Deals

J&J Acquires Immune-Mediated Diseases Specialist Proteologix in a Deal Worth Up to USD 850 Million

Fineline Cube May 17, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare giant, has announced a deal to...

Posts pagination

1 … 319 320 321 … 626

Recent updates

  • United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential
  • Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer
  • Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD
  • MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks
  • Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential

Company Deals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

Company Drug

Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD

Company Deals

MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.